<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02245490</url>
  </required_header>
  <id_info>
    <org_study_id>527.30</org_study_id>
    <nct_id>NCT02245490</nct_id>
  </id_info>
  <brief_title>Study to Characterise the Effect of Tamsulosin on Lower Urinary Tract Symptoms (LUTS) and Detrusor Motor Activity in Patients Affected by Benign Prostatic Hyperplasia (BPH) and Storage Urinary Symptoms</brief_title>
  <official_title>BLADDER (BPH, LUTS And Detrusor: Dual Effect Research) Study: A Multicentre, Double-blind, Randomised, Parallel Group, Placebo-controlled Study, Aimed at Characterising the Effect of Tamsulosin on Lower Urinary Tract Symptoms (LUTS) and Detrusor Motor Activity in Patients Affected by Benign Prostatic Hyperplasia (BPH) and Storage Urinary Symptoms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Study to evaluate the efficacy of tamsulosin on storage symptoms and detrusor motor activity
      in patients with LUTS suggestive of BPH and relevant storage symptoms
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2003</start_date>
  <primary_completion_date type="Actual">April 2004</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in mean number of micturitions per day</measure>
    <time_frame>Up to 12 weeks after first drug administration</time_frame>
    <description>As reported in the Urinary Chart</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in mean number of urgency episodes per day</measure>
    <time_frame>Up to 12 weeks after first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in voided volume per micturition</measure>
    <time_frame>Up to 12 weeks after first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in International Prostate Symptom Score (I-PSS) on storage and voiding sub-scores</measure>
    <time_frame>Up to 12 weeks after first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Quality of Life in BPH patients with urinary symptoms (QUIBUS) Italian Score QUIBUS Symptom Score (QUISS) -11 on storage and voiding sub-scores</measure>
    <time_frame>Up to 12 weeks after first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in International Index of Erectile Function (IIEF)</measure>
    <time_frame>Up to 12 weeks after first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Uroflowmetry</measure>
    <time_frame>Up to 12 weeks after first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Qmax</measure>
    <time_frame>Up to 12 weeks after first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in volume at the first contraction</measure>
    <time_frame>Up to 12 weeks after first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of unstable contractions</measure>
    <time_frame>Up to 12 weeks after first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum amplitude of unstable contractions</measure>
    <time_frame>Up to 12 weeks after first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>Up to 12 weeks after first drug administration</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">153</enrollment>
  <condition>Prostatic Hyperplasia</condition>
  <arm_group>
    <arm_group_label>Tamsulosin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamsulosin HCl controlled release capsules</intervention_name>
    <arm_group_label>Tamsulosin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching placebo capsule</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male outpatients aged 50-80 years

          -  LUTS suggestive of BPH

          -  Medical history: storage symptoms (frequency, urgency) for at least 6 months

          -  Urinary Chart:

               -  At least 8 micturitions per 24 hours on average, over the week of the screening
                  period (check urinary chart at Visit 2)

               -  Urgency (strong desire to void): at least once per 24 hours on average, over the
                  week of the screening period (check urinary chart at Visit 2)

          -  I-PSS ≥ 13 at randomisation (Visit 3)

          -  Qmax: &gt; 4 ml/sec at randomisation (Visit 3), with a voiding volume of at least 150 ml

          -  Prostate Specific Antigen (PSA) &lt; 2.5 ng/ml or between 2.5 and 10 ng/ml, if cancer is
             ruled out with the usual procedures of each centre (Visit 1; results before Visit 3)

          -  Written Informed Consent for participation to the study

        Exclusion Criteria:

          -  Patients with a known history or a diagnosis at the time of the screening visit (Visit
             1) of the following conditions:

          -  Urological disturbances

               -  Medical history of pelvic surgery

               -  Palpable bladder at the physical examination, or residue urinary volume &gt; 400 ml

               -  Known neurological bladder disorder

               -  Bladder neck stenosis

               -  Urethral stricture

               -  Bladder or prostatic cancer

               -  Bladder stone

               -  Severe diverticulum of the bladder

               -  Symptomatic urinary tract infection during last month, or recurrent urinary tract
                  infections (more than 2 during last year)

               -  Haematuria of unknown origin

               -  Diseases which may affect micturition (i.e., diabetes mellitus)

          -  Cardiovascular diseases (if they occurred in the last 6 months)

               -  Myocardial infarction

               -  Instable angina

               -  Clinically significant ventricular arrhythmias

               -  Heart failure (NYHA classes III/IV)

               -  Orthostatic hypotension

               -  Cerebral stroke

          -  Neurological diseases (if their severity might compromise the correct performance of
             the trial)

               -  Senile dementia

               -  Multiple sclerosis

               -  Parkinson's disease

               -  Psychiatric disturbances

          -  Hepatic or renal insufficiency (biochemistry values 15% outside normal lab ranges,
             being regarded as clinically relevant by the investigator)

          -  Clinically significant abnormality in the haematological, blood chemistry and urinary
             values evidenced on the samples taken at the screening visit (Visit 1)

          -  Patients who are taking or have been taking α-blockers for BPH or for hypertension, or
             phytotherapy for BPH within the previous 6 weeks

          -  Patients who were taking or have been taking:

               -  α-blockers for BPH or for hypertension within the previous 4 weeks

               -  phytotherapy for BPH or mepartricin within the previous 4 weeks

               -  finasteride within the previous 6 months

               -  anticholinergics within the previous 4 weeks

               -  antidiuretics within the previous 4 weeks

               -  concomitant drugs which may influence the pharmacodynamic or pharmacokinetic
                  properties of tamsulosin. In particular: α-blockers and mixed α-β-blockers, α-
                  agonists, anti-cholinergics

          -  Patients who are or have been taking part in a clinical study within the previous 3
             months

          -  Patients who have had hypersensitivity or allergic reactions to previously prescribed
             α- blocker(s)

          -  Patients judged by the investigator to be inappropriate for inclusion in the study
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
  </link>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 18, 2014</study_first_submitted>
  <study_first_submitted_qc>September 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2014</study_first_posted>
  <last_update_submitted>September 18, 2014</last_update_submitted>
  <last_update_submitted_qc>September 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 19, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Lower Urinary Tract Symptoms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamsulosin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

